TransCon CNP 3.9 mg CNP-38/vial, Placebo for TransCon CNP
ASND0045
Phase 2 small_molecule active
Quick answer
TransCon CNP 3.9 mg CNP-38/vial, Placebo for TransCon CNP for Achondroplasia in Children and Adolescents is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Achondroplasia in Children and Adolescents
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active